tbuckley/cabot-search huggingface dataset:
Coronary Thrombolysis
Authors: Harris A. Lappin
Journal: Annals of Internal Medicine (1990)

Letters and Corrections15 July 1990Coronary ThrombolysisHarris A. Lappin, MDHarris A. Lappin, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-113-2-171 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors:Dr. Collen's article (1) was very thought-provoking and, at the same time, distressing. At issue is not whether the actual recanalization rates, as quoted by Dr. Collen, are correct, but rather whether we should use less efficient care to save money. I am in private practice in cardiology and am very cognizant of the cost of every therapy provided for my patients; I am equally aware that my obligation is to do my best for my patients. In that regard, how could I prescribe therapy with a drug that is less efficient in opening an obstructed coronary...Reference1. Collen D. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? Ann Intern Med. 1990;112:529-38. LinkGoogle Scholar1. Collen D. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? Ann Intern Med. 1990;112:529-38. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Harris A. Lappin, MDAffiliations: Louisiana Cardiology Associates Baton Rouge, LA 70808 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 July 1990Volume 113, Issue 2Page: 171-171KeywordsDrug therapy ePublished: 1 December 2008 Issue Published: 15 July 1990 PDF downloadLoading ...
Site of Accumulation of Red Blood Cells and Plasma During Rapid Plasma Expansion
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The best health care system in the world?
Authors: V. R. Fuchs
Journal: JAMA (1992)

"AMERICANS enjoy the best health care system in the world." So says President Bush, and many physicians agree with this claim. But frequent repetition doesn't make it true. What kind of evidence would an objective observer examine to evaluate different systems of health care? Is it possible to determine the best system unambiguously, or does the choice depend on the criteria used? The "best" health care system may be like the "best" spouse—it all depends on what one is looking for. Physicians, for instance, may assign values to system characteristics that differ markedly from those assigned by the public. Even within the profession, each specialty may have a different point of view and reach different conclusions about the system, eg, radiologists vs family physicians. Naoki Ikegami, a Japanese psychiatrist, has suggested three criteria for assessing "best medical practice": (1) maintenance of technical standards in diagnosis and treatment; (2) preventive measures
OBITUARY
Authors: Albert Touraine
Journal: British Journal of Dermatology (1961)

Journal Article OBITUARY Get access Albert Touraine Albert Touraine Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 73, Issue 8-9, 1 August 1961, Pages 346–347, https://doi.org/10.1111/j.1365-2133.1961.tb14460.x Published: 01 August 1961
Table and Figure Errors
Authors: Lin Chen, Davidson Hamer
Journal: JAMA (2018)

Brian F. Gage, MD, MSc; Anne R. Bass, MD; Hannah Lin, BA; Scott C. Woller, MD; Scott M. Stevens, MD; Noor Al-Hammadi, MBChB, MPH; Juan Li, MPH; Tomás Rodríguez Jr, MS; J. Philip Miller, AB; Gwendolyn A. McMillin, PhD; Robert C. Pendleton, MD; Amir K. Jaffer, MD, MBA; Cristi R. King, BS; Brandi DeVore Whipple, BS; Rhonda Porche-Sorbet, MS; Lynnae Napoli, BS; Kerri Merritt, BA; Anna M. Thompson, BA; Gina Hyun, MD; Jeffrey L. Anderson, MD; Wesley Hollomon, MD, MBA; Robert L. Barrack, MD; Ryan M. Nunley, MD; Gerard Moskowitz, PhD; Victor Dávila-Román, MD; Charles S. Eby, MD
Experience with Radioactive Tantalum Wire as a Source for Interstitial Therapy
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Detection of lung cancer
Authors: D. M. Eddy
Journal: JAMA (1981)

<h3>In Reply.—</h3> The editorial cited by Dr Eddy was provoked by the February 1980 ACS report on "The Cancer-Related Health Checkup."<sup>1</sup>That report, prepared for the ACS by Dr Eddy, emphasized that its recommendations pertained only to early detection of cancer on an individual basis and not to "mass screening programs at public expense."<sup>1</sup> Our editorial comment was likewise confined to individual case-finding initiated by patients.<sup>2</sup>We are on record as being opposed to noncontrolled large-scale screening programs initiated by any organization. Our concern is that Dr Eddy seems to use "screening" and "early detection" interchangeably. In his letter he writes: the ACS is aware that x-ray films can detect cancers in asymptomatic persons and that the cancers often appear to be detected in early stages. The Society is also aware, however, of the many biases that can cause an interpretation of staging information and case-survival rates
Highlights
Journal: JAMA Dermatology (2018)

Assessing Psoriasis in Clinical Trials 1137There is no consensus on which measurements should be used in clinical trials of psoriasis therapies.In this Delphi survey study by Callis Duffin et al, patients, clinicians, and other stakeholders agreed that the following 6 domains should be measured in all psoriasis clinical trials: (1) skin manifestations, both primary and location (palmoplantar or scalp); (2) psoriasis and psoriatic arthritis symptoms;(3) investigator global assessment; (4) patient global assessment;(5) health-related quality of life; and (6) treatment satisfaction.These 6 domains should be the mandatory minimum measures in all future psoriasis interventional trials.
Disseminated Coccidioidomycosis.
Authors: J. R. Graybill
Journal: Annals of Internal Medicine (1972)

Meeting Abstracts1 May 1972Disseminated Coccidioidomycosis.J. R. Graybill, J. A. Reinarz, M.D., F.A.C.P.J. R. GraybillSearch for more papers by this author, J. A. Reinarz, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-76-5-879_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOver a 6-year period 13 patients were treated at Wilford Hall USAF Medical Center, Lackland AFB, Tex., for disseminated coccidioidomycosis. The correct diagnosis was infrequently made from initial history and physical examination. Eleven patients had acquired their disease in either Texas or Arizona, and two patients were in foreign countries when they became symptomatic. Most did not give a history suggesting recent pulmonary disease and presented with signs or symptoms referable to either cutaneous or skeletal lesions. Cocci spherules seen in tissue sections or aspirates provided the correct diagnosis in 10 of 13 patients. Complement fixation titers were at some... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Lackland Air Force Base, Tex. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByInfectious diseases: annual review of significant publications.Chapter 13. Antifungal Agents 1 May 1972Volume 76, Issue 5Page: 879-879KeywordsCoccidioidomycosisLesionsPulmonary diseasesSigns and symptoms Issue Published: 1 May 1972 PDF DownloadLoading ...
Environmental influences on implanted cardiac pacemakers
Authors: S. M. Michaelson
Journal: JAMA (1971)

Cardiac pacemaker activity is subject to interference from a variety of electrical and radiofrequency fields. As new and more sensitive types of pacemakers are developed, the interference problem becomes more complex. Some potential sources of interference for implanted pacemaker systems include<sup>1</sup>radio frequency (RF) transmission such as radio and television broadcasting; RF energy from miscellaneous sources such as microwave ovens and radar; carrier current on power transmission lines; magnetic fields around power transformers and conductors carrying electric current; and arcing and sparking electrical equipment such as power tools, commutator motors, and ignition systems of aircraft, automobile, motorcycle, and lawnmowers. Medical equipment, such as diathermy, electrocautery, neurosurgical stimulators, and high-voltage radiation therapy units, are common sources of electrical interference within the hospital. The fixed-rate (asynchronous) pacemaker has a lowfrequency oscillator designed to deliver pulses at a desired cardiac stimulation rate. Once implanted, such units are fairly insensitive to electrical interference,
REGARDING THE PRACTICE OF MEDICINE IN KENTUCKY.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Food security in uncertain times
Authors: None The Lancet Planetary Health
Journal: The Lancet Planetary Health (2020)

Food systems are fundamental to human health and flourishing and constitute one of the major pathways of human impact on the environment. Impacts include habitat loss (which is implicated in the spread of zoonotic disease like COVID-19), water resource depletion, perturbation of biochemical cycling (including greenhouse gas emissions), pollution, and waste to name just a few. The performance of the food system therefore matters a great deal. The systems we employ influence who has enough to eat and who does not, how much environmental degradation we cause and where it accrues, and also influence the extent to which people consume healthy and sustainable meals right across the wealth spectrum.
PLoS Medicine Issue Image | Vol. 3(2) February 2006
Journal: PLoS Medicine (2006)

This image is from a series of photographic works entitled Inaction, which includes both black and white photographs and a digital video of individual bird and squirrel carcasses. Using a medium-format view camera to capture an impeccable amount of detail from each form, the viewer is seduced into observing the unavoidable details of the world. Against the abstract expressionist canvas of the roadside, death becomes both an enticing and an unsentimental object of reflection. While the formulaic framing of the subject refers loosely to a tradition of medical cataloging, there is an underlying and conflicting sense of concern for the deceased. Margaret Shear is a San Francisco-based artist and designer. She received Bachelor of Arts degrees in both Studio Art and Science, Technology, and Society from Stanford University. Her recent work incorporates depictions of inanimate objects as a means of exploring intimacy and empathy in a world increasingly decentralized by technology. Image Credit: Margaret Shear (http://www.shearshear.com)
Retrograde injections of formaldehyde into the biliary tree induce alterations of biliary epithelial function in rats
Authors: M Dumont, C D'Hont, A Moreau, H Mbape, G Feldmann, S Erlinger
Journal: Hepatology (1996)

Formaldehyde may induce severe lesions of intrahepatic and extrahepatic bile ducts. The purpose of this study was to examine in vivo the functional consequences of an alteration of the biliary epithelium induced by a retrograde intrabiliary injection of formaldehyde in rats. After basal bile collection, a 10% formaldehyde solution was injected into the biliary tree of anesthetized rats, and the cannula was occluded for 30 minutes. Choleresis was then reestablished, and bile flow, bile acid, and bicarbonate secretion were measured both spontaneously and during ursodeoxycholate infusions. Formaldehyde injections induced a significant increase in bile flow and a marked inhibition of ursodeoxycholate–induced increase in biliary bicarbonate concentration and secretion. Biliary glucose secretion, which is normally very low, was increased about 20–fold in animals injected with formaldehyde. Histological and ultrastructural examination of the liver showed alterations of biliary epithelial cells, whereas hepatocytes, bile canaliculi, and canalicular tight junctions remained normal. Hepatocytic excretory function, as assessed by biliary secretion of bile acids, was not affected. It was concluded that short–term formaldehyde intrabiliary injections cause an inhibition of ursodeoxycholate–induced hypersecretion of bicarbonate, an increase in biliary glucose secretion, and selective structural alterations of biliary epithelial cells. These results suggest that formaldehyde retrograde biliary injection may be a useful model to study alterations of biliary epithelial function in vivo .
Some bottlenecks towards family medicine
Authors: L. P. Levitt
Journal: JAMA (1971)

When I agreed to make this presentation, I had not realized what a difficult task it would be at this moment in time. Deans are not known for their reticence in talking, and are given to great bursts of eloquence on matters of budgets, fund-raising and faculty appointments, as well as the ubiquitous problems of curriculum. I had thought I might speak about the role of the general practitioner in Europe, having but a few weeks ago returned from a World Health Organization fellowship which took me to eight countries; by the end of the week in each country, I wasn't so sure I understood what prevailed there, since opinions were too varied and anecdotal. I then considered relating some data concerning our preceptorship program with the DuPage County Medical Society, now of three years' vintage. It continues to be quite successful, but somehow it did not seem fitting as
Estrogens and Development
Authors: John A. McLachlan, Retha R. Newbold
Journal: Environmental Health Perspectives (1987)

The normal development of the genital organs of mammals, including humans, is under hormonal control. A role for the female sex hormone estrogen in this process is still unclear. However, exposure of experimental animals or humans to the potent exogenous estrogen, diethylstilbestrol (DES), results in persistent differentiation effects. Since many chemicals in the environment are weakly estrogenic, the possibility of hormonally altered differentiation must be considered.
EXTENSION OF HOSPITAL CORPS DRILL IN THE ARMY.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medicare To Help Pay for Cervical Cancer Screening Every 3 Years
Journal: JNCI Journal of the National Cancer Institute (1990)

Journal Article Medicare To Help Pay for Cervical Cancer Screening Every 3 Years Get access JNCI: Journal of the National Cancer Institute, Volume 82, Issue 15, 1 August 1990, Pages 1242–1243, https://doi.org/10.1093/jnci/82.15.1242 Published: 01 August 1990
Program organization following corporate merger of community hospitals
Authors: E. C. Shortliffe
Journal: JAMA (1968)

To compress the history of developments leading to the creation of the Wilmington Medical Center and then to comment further upon program development since that creation, and to do all of this briefly presents me with many problems. I have therefore chosen to present only a summary of the history leading to our development. Between the period from 1959 through 1963, in Wilmington among the boards of directors of three equal-sized community general hospitals, there was a preoccupation with rising operating and capital costs and with the deterioration of medical education as measured in terms of the quantity and quality of intern and resident applicants, as well as the quality of ongoing medical education for the members of the three medical staffs. Efforts were made through a mechanism of cooperation, not only to resolve some of these problems but to examine their implications and possible new and somewhat startling methods
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies.
Authors: Manish Sharma, Daniel Virgil Thomas Catenacci, Theodore Karrison, Kenisha Allen, Jaclyn D Peterson, Robert de Wilton Marsh, Mark Kozloff, Blase N. Polite, Hedy Lee Kindler
Journal: Journal of Clinical Oncology (2014)

4125 Background: FOLFIRINOX improves survival compared with gemcitabine in advanced pancreatic cancer (PC), but at the cost of significant toxicity (Conroy, NEJM2011). UGT1A1 clears SN-38, the active metabolite of irinotecan (IRI); UGT1A1 gene polymorphisms that reduce enzymatic activity predispose to severe IRI toxicity. We hypothesized that dosing mFOLFIRINOX based on UGT1A1*28 genotype could prevent toxicity. Thus, the primary objective of this study (NCT01643499) was to determine whether genotype-guided dosing of IRI in mFOLFIRINOX is tolerable. A secondary objective was to describe objective response rates (ORR; by RECIST 1.1) in PC, biliary tract cancers (BTC), and gastric cancer (GC). Methods: mFOLFIRINOX was given every 14 days. CT scans were obtained every 8 weeks. UGT1A1 *1/*1, *1/*28, and *28/*28 pts received initial IRI doses of 180, 135, and 90 mg/m2, respectively. 5-FU dose was 2400 mg/m2 over 46 hours (no bolus); leucovorin 400 mg/m2; oxaliplatin 85 mg/m2. Prophylactic pegfilgrastim was not allowed in cycle 1 (28 days), unless clinically indicated. DLT during cycle 1 was defined as Grade (Gr) 3/4 neutropenia with fever; Gr 4 neutropenia lasting ≥ 5 days; Gr 4 thrombocytopenia, or Gr 3/4 non-hematologic toxicity despite optimal medical management. Doses were tolerable if the DLT rate during cycle 1 was ≤ 33% with 70-80% statistical confidence, which required ≤ 2 DLTs in 15 pts. Results: 40 pts were evaluable for tolerability: 19 PC, 14 BTC, 7 GC. DLTs were observed in 2 of 15 *1/*1 pts (both neutropenic fevers); 2 of 16 *1/*28 pts (Gr 3 fatigue, diarrhea; Gr 3 fatigue); and 3 of 9 *28/*28 pts (2 neutropenic fevers; Gr 3 abdominal pain). Neutropenic fever was the most common DLT (4/7; 57%). To date, 35 pts are evaluable for response. ORR: 10/18 (56%) PC; 4/13 (31%) BTC; 3/4 (75%) GC. Conclusions: mFOLFIRINOX is tolerable in UGT1A1*1/*1 pts at the standard IRI dose of 180 mg/m2 and in *1/*28 pts at a reduced dose of 135 mg/m2. *28/*28 pts cannot tolerate a reduced dose of 90 mg/m2. Accrual is ongoing for expansion cohorts in PC and BTC with prophylactic pegfilgrastim. Clinical trial information: NCT01643499. UGT1A1 genotype Initial IRI dose (mg/m2) # DLTs / # pts *1/*1 180 2/15 *1/*28 135 2/16 *28/*28 90 3/9